DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Net Loss Per Share

Note 11 - Net Loss Per Share

6 Months Ended

Jun. 30, 2023

11. Net Loss Per Share

We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.

The following table summarizes our calculation of net loss per common share for the periods presented (in thousands, except share and per share data):

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Net loss	$	(4,477	)	$	(3,358	)	$	(9,749	)	$	(6,866	)
Weighted average shares outstanding—basic and diluted		27,312,008			26,443,067			26,882,858			26,443,067
Basic and diluted net loss per share	$	(0.16	)	$	(0.13	)	$	(0.36	)	$	(0.26	)

The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Employee and non-employee stock options		3,643,513		2,623,998		3,643,513		2,623,998
Common shares issuable under common share purchase warrants		205,000		265,000		205,000		265,000
Common shares issuable under deferred stock units		213,905		134,402		213,905		134,402
Common shares issuable upon vesting of restricted stock units		8,578		—		8,578		—